Jemin Gajipara, MD
Pain Medicine · Dallas, TXNPI 1922205939
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $3,347 and has fallen 63.2% since, to $1,232 in 2025.
Across 149 payments — averaging $46.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Curonix LLC$663
- Collegium Pharmaceutical, Inc.$467
- Tersera Therapeutics LLC$213
- Protega Pharmaceutials Inc$152
- Boston Scientific$112
- plus $874 from 18 others
What the payments were for
- Travel & lodging$3,32748%
- Food & beverage$3,59052%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 50 | $4,457 |
| Curonix LLC | 10 | $663 |
| Collegium Pharmaceutical, Inc. | 28 | $467 |
| Tersera Therapeutics LLC | 10 | $213 |
| Protega Pharmaceutials Inc | 7 | $152 |
| Boston Scientific | 5 | $112 |
| Abbott | 5 | $108 |
| Vertex | 5 | $104 |
| Biotronik NRO, Inc. | 1 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $101 |
| Valinor Pharma, LLC | 5 | $101 |
| Azurity Pharmaceuticals, Inc. | 4 | $76 |
| Nalu Medical, Inc. | 2 | $42 |
| Assertio Therapeutics, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $31 |
| Averitas Pharma Inc. | 1 | $30 |
| Stryker | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Spinal Simplicity, LLC | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Globus Medical | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,938 in reported general payments places this provider in the 65th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nucynta ErTapentadol Hcl | 121 | $134,300 |
| Xtampza ErOxycodone Myristate | 98 | $80,325 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,609 | $67,614 |
| RoxybondOxycodone Hcl | 19 | $41,499 |
| Buprenorphine | 174 | $32,511 |
| BelbucaBuprenorphine Hcl | 34 | $30,066 |
| Tramadol Hcl ErTramadol Hcl | 423 | $25,677 |
| NucyntaTapentadol Hcl | 21 | $23,891 |
| MovantikNaloxegol Oxalate | 51 | $21,991 |
| Hysingla ErHydrocodone Bitartrate | 29 | $20,618 |
| Diclofenac Sodium | 62 | $14,820 |
| Fentanyl | 111 | $11,487 |
| Morphine Sulfate ErMorphine Sulfate | 323 | $10,352 |
| Buprenorphine Hcl | 385 | $9,884 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 312 | $8,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Belbuca, Nucynta | $467 | $268,582274 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl, Morphine Sulfate, Buprenorphine-Naloxone | $21 | $50,326734 claims |
| Protega Pharmaceutials IncRoxybond | $152 | $41,49919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Dallas
- Justin ThompsonDallas$45K
- Demaceo HowardDallas$39K
- Melissa MurphyGrapevine$653K
- Shiraz YazdaniLubbock$514K
- Aaron CalodneyTyler$296K
- Candice BurnetteSugar Land$265K
- Ashley Bailey-ClassenFort Worth$244K
- Grant ChenHouston$175K
- Gunjan PatelHouston$166K
- Anthony BergRockwall$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.